Chemical Storage in the Contract Environment

| January 24, 2017

article image
When we think of chemical storage we tend to think of large warehouses or factories designed to store chemicals in large quantities. However, the standards and regulatory requirements required of large chemical facilities still have to be met by smaller facilities. In smaller facilities and laboratories, chemical storage is often secondary to other tasks and functions. There are still a number of things you must do even if your primary business is not managing chemicals. In this blog, we’ll explore some of the necessary steps to properly manage chemicals as well as protect employee well-being.

Spotlight

DAISO Fine Chem USA, INC.

We thank our customers for the great support over these past years. We are happy to announce that in October 26th, 2015, DAISO Co. Ltd. celebrated its 100th anniversary. For that reason, DAISO Co. Ltd. has changed back to its original name Osaka Soda, Co. Ltd. Our subsidiaries, DAISO Fine Chem USA, Inc. in Torrance, CA, USA, and DAISO Fine Chem GmbH in Düsseldorf, Germany will retain its name bringing you the highest quality DAISOGEL spherical silica for chromatography.

OTHER ARTICLES

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Spotlight

DAISO Fine Chem USA, INC.

We thank our customers for the great support over these past years. We are happy to announce that in October 26th, 2015, DAISO Co. Ltd. celebrated its 100th anniversary. For that reason, DAISO Co. Ltd. has changed back to its original name Osaka Soda, Co. Ltd. Our subsidiaries, DAISO Fine Chem USA, Inc. in Torrance, CA, USA, and DAISO Fine Chem GmbH in Düsseldorf, Germany will retain its name bringing you the highest quality DAISOGEL spherical silica for chromatography.

Events